| |APRIL 20268LILLY'S EBGLYSS SHOWS LASTING RELIEF FOR MODERATE SEVERE ECZEMAEli Lilly's eczema drug Ebglyss (lebrikizumab) is making waves with new long?term response, lasting relief for people with moderate-to-severe severe Eczema. The latest late-stage study results reveal that the biologic therapy delivered durable disease control and relief from persistent itch for up to four years when given as a once?monthly maintenance injection, marking a major advance in chronic eczema care.The study tracked patients in an open-label extension after initial trials, and the results showed that many continued to experience clear or nearly clear skin over the long term. For people living with moderate?to?severe eczema, this kind of sustained benefit represents a shift from short-term symptom control to true ongoing disease management.Dermatologists have long pointed out how chronic atopic dermatitis can take a toll on quality of life, with relentless itching, inflammation, and skin damage. The new Ebglyss data suggest that patients can maintain symptom relief and skin improvement with regular treatment, reducing reliance on frequent steroid creams and reactive therapies.Ebglyss works by targeting interleukin 13 (IL 13), a key driver of inflammation in atopic dermatitis, and Lilly has positioned it as a valuable biologic option for patients whose eczema isn't controlled by topical medicines alone. The drug's long-term effectiveness and consistent safety profile could influence how doctors choose therapies for severe eczema moving forward.While some newer competitors are emerging in the atopic dermatitis treatment landscape, the latest results for Ebglyss underline its potential to offer reliable, enduring relief from both skin symptoms and chronic itch. These findings may help doctors and patients make more confident, informed decisions about long-term biologic treatment strategies. POTOP STORIESGOVERNMENT OF INDIA PUSHES GENERIC MEDICINES IN HOSPITALSGovernment of India is stepping up its push for generic medicines in hospitals, urging healthcare providers to prescribe and stock low-cost alternatives to branded drugs.The move aims to cut treatment expenses and improve access to affordable care, especially for patients who pay out of pocket.The focus on generic medicines in hospitals comes as drug costs continue to make up a large share of medical bills across the country. Generics contain the same active ingredients and deliver the same therapeutic effect as branded drugs, but at a fraction of the price, making them a key tool in reducing healthcare costs.Officials are encouraging both public and private hospitals to prioritize generics in prescriptions and procurement. The push aligns with ongoing efforts to expand access through government-backed programs that supply affordable medicines nationwide. By increasing the use of generics, authorities expect to ease the financial burden on patients and strengthen overall healthcare affordability.At the same time, the shift has sparked debate within the medical community. Some doctors have raised concerns about variations in quality among manufacturers and the potential loss of control over specific drug choices. There are also worries that pharmacists could influence which products are dispensed if prescriptions are not brand-specific.Despite these concerns, the government continues to emphasize stricter quality checks and regulatory oversight to ensure that approved generics meet safety and efficacy standards. The broader goal is to build trust in generics while making essential treatments more accessible.The latest push signals a stronger policy direction toward affordable healthcare, with generic medicines in hospitals expected to play a central role in lowering costs and expanding patient access across India. PO
< Page 7 | Page 9 >